Follow

Books from 2019

Link

Axial Spondyloarthritis, Philip Mease and Muhammad Asim Khan

Link

Biologic Treatment of Axial Spondyloarthritis, Philip Mease and F. Van den Bosch

Submissions from 2018

Link

Anti-Inflammatory Effects of Intra-Articular Hyaluronic Acid: A Systematic Review., Roy Altman, Asheesh Bedi, Ajay Manjoo, Faizan Niazi, Peter Shaw, and Philip Mease

Link

GRAPPA 2017 Project Report., Kristina Callis Duffin, Oliver FitzGerald, Artie Kavanaugh, Philip Mease, Joseph F Merola, Alexis Ogdie, Denis O'Sullivan, Soumya M Reddy, Christopher T Ritchlin, and Laura C Coates

Link

Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study., Alberto Cauli, Dafna D Gladman, Alessandro Mathieu, Ignazio Olivieri, Giovanni Porru, Paul P Tak, Claudia Sardu, Raffaele Scarpa, Antonio Marchesoni, William J Taylor, Carlo Salvarani, Joachim Kalden, Ennio Lubrano, Sueli Carneiro, Matteo Piga, Alberto Floris, Francesca Desiati, John A Flynn, Salvatore D'Angelo, Arno W R van Kuijk, Maria Grazia Catanoso, Francesco Caso, Paolo Contu, Ilona Ujfalussy, Philip S Helliwell, and Philip Mease

Link

Remission in psoriatic arthritis-where are we now?, Laura C Coates, Philip G Conaghan, Maria Antonietta D'Agostino, Maarten De Wit, Oliver FitzGerald, Tore K Kvien, Rik Lories, Philip Mease, Peter Nash, Georg Schett, Enrique R Soriano, and Paul Emery

Link

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis., Laura C Coates, Oliver FitzGerald, Joseph F Merola, Josef Smolen, Leonieke J J van Mens, Heidi Bertheussen, Wolf-Henning Boehncke, Kristina Callis Duffin, Willemina Campbell, Maarten de Wit, Dafna Gladman, Alice Gottlieb, Jana James, Arthur Kavanaugh, Lars Erik Kristensen, Tore K Kvien, Thomas Luger, Neil McHugh, Philip Mease, Peter Nash, Alexis Ogdie, Cheryl F Rosen, Vibeke Strand, William Tillett, Douglas J Veale, and Philip S Helliwell

Link

Minimal Disease Activity among Active Psoriatic Arthritis Patients Treated with Secukinumab: 2-year Results from the FUTURE 2 Study., Laura C Coates, Philip Mease, Laure Gossec, Bruce Kirkham, Bintu Sherif, Corine Gaillez, Shephard Mpofu, Steffen M Jugl, Chetan Karyekar, and Kunal K Gandhi

Link

Opioids vs Nonopioids for Chronic Back, Hip, or Knee Pain., Edward Covington, Charles Argoff, and Steven P Stanos

Link

Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis., Mark C Genovese, Michael E Weinblatt, Philip J Mease, Jacob A Aelion, Paul M Peloso, Kun Chen, Yihan Li, John Liu, Ahmed A Othman, Amit Khatri, Heikki T Mansikka, and Piotr Leszczynski

Link

The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database., Dafna D Gladman, Laura C Coates, Deepak R Jadon, William Tillett, Philip Mease, and Marijn Vis

PDF

Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies., Dafna D Gladman, Arthur Kavanaugh, Juan J Gómez-Reino, Jürgen Wollenhaupt, Maurizio Cutolo, Georg Schett, Eric Lespessailles, Benoit Guerette, Nikolay Delev, Lichen Teng, Christopher J Edwards, Charles A Birbara, and Philip J Mease

Link

The Effect of Psoriatic Arthritis on Ixekizumab Clinical Outcomes in Moderate-to-Severe Psoriasis Patients: A Post Hoc Analysis., Alice B Gottlieb, Kim A Papp, Charles A Birbara, Catherine L Shuler, Russel Burge, Janelle Erickson, Lisa Kerr, and Philip J Mease

Link

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)., Alice B Gottlieb, Vibeke Strand, Mitsumasa Kishimoto, Philip Mease, Diamant Thaçi, Julie Birt, Chin H Lee, Catherine L Shuler, Chen-Yen Lin, and Dafna D Gladman

Link

Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: A prospective cohort study., Pil Højgaard, Karen Ellegaard, Sabrina Mai Nielsen, Robin Christensen, Jørgen Guldberg-Møller, Christine Ballegaard, Lene Dreyer, Philip Mease, Maarten de Wit, Lone Skov, Bente Glintborg, Henning Bliddal, Else Marie Bartels, Kirstine Amris, and Lars Erik Kristensen

Link

A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative., Pil Højgaard, Louise Klokker, Ana-Maria Orbai, Kim Holmsted, Else M Bartels, Ying Ying Leung, Niti Goel, Maarten de Wit, Dafna D Gladman, Philip Mease, Lene Dreyer, Lars E Kristensen, Oliver FitzGerald, William Tillett, Laure Gossec, Philip Helliwell, Vibeke Strand, Alexis Ogdie, Caroline B Terwee, and Robin Christensen

Link

Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting., Richard Holland, William Tillett, Alexis Ogdie, Ying Y Leung, Dafna D Gladman, Kristina Callis Duffin, Laura C Coates, Philip Mease, Lihi Eder, Vibeke Strand, Musaab Elmamoun, Pil Højgaard, Jeffrey Chau, Maarten de Wit, Niti Goel, Chris A Lindsay, Oliver FitzGerald, Bev Shea, Dorcas Beaton, and Ana-Maria Orbai

Link

Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study., Robert Landewé, Joachim Sieper, Philip Mease, Robert D Inman, Robert G Lambert, Atul Deodhar, Helena Marzo-Ortega, Marina Magrey, Uta Kiltz, Xin Wang, Mei Li, Sheng Zhong, Nael M Mostafa, Apinya Lertratanakul, Aileen L Pangan, and Jaclyn K Anderson

PDF

Classification and Outcome Measures for Psoriatic Arthritis., Ying Ying Leung, Alexis Ogdie, Ana-Maria Orbai, William Tillett, Laura C Coates, Vibeke Strand, Philip Mease, and Dafna D Gladman

Link

Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study., Iain B McInnes, Philip Mease, Georg Schett, Bruce Kirkham, Vibeke Strand, Nicole Williams, Todd Fox, Luminita Pricop, Steffen M Jugl, and Kunal K Gandhi

Link

Current and Emerging Treatments for Psoriatic Arthritis, Philip Mease

Link

Considerations for the definition of remission criteria in psoriatic arthritis., Philip Mease and Laura C Coates

Link

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial., Philip Mease, Laura C Coates, Philip S Helliwell, Mykola Stanislavchuk, Anna Rychlewska-Hanczewska, Anna Dudek, Walid Abi-Saab, Chantal Tasset, Luc Meuleners, Pille Harrison, Robin Besuyen, Annegret Van der Aa, Neelufar Mozaffarian, Joy M Greer, Rebecca Kunder, Filip Van den Bosch, and Dafna D Gladman

Link

Phase 2 Study of ABT-122, a TNF- and IL-17A-Targeted Dual Variable Domain Immunoglobulin, in Psoriatic Arthritis With Inadequate Methotrexate Response., Philip Mease, Mark C Genovese, Michael E Weinblatt, Paul M Peloso, Kun Chen, Ahmed A Othman, Yihan Li, Heikki T Mansikka, Amit Khatri, Neil Wishart, and John Liu

Link

Tofacitinib for Psoriatic Arthritis., Philip Mease and Dafna Gladman

Link

Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA)., Philip Mease, Dafna D Gladman, Ahmed S Samad, Laura C Coates, Lyrica X H Liu, Girish A Aras, David H Collier, and James B Chung

Link

CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study., Philip J Mease, Slawomir Jeka, Juan Jose Jaller, Tasanee Kitumnuaypong, Worawit Louthrenoo, Herman Mann, Galina Matsievskaia, Enrique R Soriano, Bin Jia, Caihong Wang, Jing Nie, and Elizabeth Hsia

PDF

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial., Philip J Mease, Arthur Kavanaugh, Andreas Reimold, Hasan Tahir, Jürgen Rech, Stephen Hall, Piet Geusens, Pascale Pellet, Evie Maria Delicha, Shephard Mpofu, and Luminita Pricop

Link

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry., Philip J Mease, Jacqueline B Palmer, Mei Liu, Arthur Kavanaugh, Renganayaki Pandurengan, Christopher T Ritchlin, Chitra Karki, and Jeffrey D Greenberg

Link

Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry., Philip J Mease, Désirée van der Heijde, Chitra Karki, Mei Liu, Yujin Park, and Jeffrey D Greenberg

PDF

Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry., Philip Mease, Chitra Karki, Mei Liu, Arthur Kavanaugh, Christopher T Ritchlin, Doquyen Hoa Huynh, Jacqueline B Palmer, and Jeffrey D Greenberg

PDF

Correction: Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial., Philip Mease, A Kavanaugh, and A Reimold

Link

Axial Spondyloarthritis, Philip Mease and Muhammad Asim Khan

Link

Safety of Ixekizumab in Patients with Psoriatic Arthritis: Results from a Pooled Analysis of Three Clinical Trials., Philip Mease, Euthalia Roussou, Gerd-Rüdiger Burmester, Philippe Goupille, Alice Gottlieb, Susan R Moriarty, Olivier Benichou, David H Adams, Wen Xu, and Peter Nash

Link

Functional impairment measurement in psoriatic arthritis: Importance and challenges., Philip Mease, Vibeke Strand, and Dafna Gladman

Link

Characterization of Patients With Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis in the US-Based Corrona Registry., Philip Mease, Désirée van der Heijde, Chitra Karki, Jacqueline B Palmer, Mei Liu, Renganayaki Pandurengan, Yujin Park, and Jeffrey D Greenberg

PDF

Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study., Philip Mease, Désirée van der Heijde, Robert Landewé, Shephard Mpofu, Proton Rahman, Hasan Tahir, Atul Singhal, Elke Boettcher, Sandra Navarra, Karin Meiser, Aimee Readie, Luminita Pricop, and Ken Abrams

Link

The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis., Philippe Mertz, Alexandre Belot, Ricard Cervera, Tyng Yu Chuah, Lorenzo Dagna, Laura Damian, Debashish Danda, David D'cruz, Gerard Espinosa, Camille Frances, David Jayne, Kong Kok Ooi, Eugene J Kucharz, Robert Lebovics, Isabelle Marie, Guillaume Moulis, Stanford Peng, Aman Sharma, Noboru Suzuki, Toshio Tanaka, Ronald Van Vollenhoven, Jean Sibilia, Jacques Eric Gottenberg, François Chasset, and Laurent Arnaud

Link

Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison., Peter Nash, Iain B McInnes, Philip Mease, Howard Thom, Matthias Hunger, Andreas Karabis, Kunal Gandhi, Shephard Mpofu, and Steffen M Jugl

PDF

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison., Peter Nash, Iain B McInnes, Philip Mease, Howard Thom, Matthias Hunger, Andreas Karabis, Kunal Gandhi, Shephard Mpofu, and Steffen M Jugl

Link

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)., Peter Nash, Philip Mease, Iain B McInnes, Proton Rahman, Christopher T Ritchlin, Ricardo Blanco, Eva Dokoupilova, Mats Andersson, Radhika Kajekar, Shephard Mpofu, and Luminita Pricop

Link

PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials., Ana-Maria Orbai, Richard Holland, Ying Ying Leung, William Tillett, Niti Goel, Robin Christensen, Neil McHugh, Laure Gossec, Maarten de Wit, Pil Højgaard, Laura C Coates, Philip Mease, Julie Birt, Lara Fallon, Oliver FitzGerald, Alexis Ogdie, Beverly Shea, Vibeke Strand, Kristina Callis Duffin, Peter Tugwell, Dorcas Beaton, and Dafna D Gladman

Link

The International Consortium for Health Outcome Measurement (ICHOM)Set of Outcomes that Matter to People Living with Inflammatory Arthritis Consensus from an international Working Group., Martijn A H Oude Voshaar, Zofia Das Gupta, Johannes W J Bijlsma, Annelies Boonen, Jeffrey Chau, Delphine S Courvoisier, Jeffrey R Curtis, Benjamin Ellis, Sofia Ernestam, Laure Gossec, Christine Hale, Jennifer Hornjeff, Katy Y Y Leung, Merav Lidar, Phillip Mease, Kaleb Michaud, Girish M Mody, Mwidimi Ndosi, Christina H Opava, Geraldo R C Pinheiro, Matthew Salt, Enrique R Soriano, William J Taylor, Maria J H Voshaar, Angelique E A M Weel, Maarten de Wit, Nico Wulffraat, Mart A F J van de Laar, and Harald E Vonkeman

Link

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force., Josef S Smolen, Monika Schöls, Jürgen Braun, Maxime Dougados, Oliver FitzGerald, Dafna D Gladman, Arthur Kavanaugh, Robert Landewé, Philip Mease, Joachim Sieper, Tanja Stamm, Maarten de Wit, Daniel Aletaha, Xenofon Baraliakos, Neil Betteridge, Filip van den Bosch, Laura C Coates, Paul Emery, Lianne S Gensler, Laure Gossec, Philip Helliwell, Merryn Jongkees, Tore K Kvien, Robert D Inman, Iain B McInnes, Mara Maccarone, Pedro M Machado, Anna Molto, Alexis Ogdie, Denis Poddubnyy, Christopher Ritchlin, Martin Rudwaleit, Adrian Tanew, Bing Thio, Douglas Veale, Kurt de Vlam, and Désirée van der Heijde

Link

Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2., Filip Van den Bosch, Philip Mease, Joachim Sieper, Dominique L Baeten, Yinglin Xia, Su Chen, Aileen L Pangan, and In-Ho Song

Link

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial., Désirée van der Heijde, James Cheng-Chung Wei, Maxime Dougados, Philip Mease, Atul Deodhar, Walter P Maksymowych, Filip Van den Bosch, Joachim Sieper, Tetsuya Tomita, Robert Landewé, Fangyi Zhao, Eswar Krishnan, David H Adams, Beth Pangallo, and Hilde Carlier

PDF

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis., Désirée van der Heijde, Atul Deodhar, Oliver FitzGerald, Roy Fleischmann, Dafna Gladman, Alice B Gottlieb, Bengt Hoepken, Lars Bauer, Oscar Irvin-Sellers, Majed Khraishi, Luke Peterson, Anthony Turkiewicz, Jürgen Wollenhaupt, and Philip Mease

Link

Correction: 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis., Désirée van der Heijde, Atul Deodhar, Oliver FitzGerald, Roy Fleischmann, Dafna Gladman, Alice B Gottlieb, Bengt Hoepken, Lars Bauer, Oscar Irvin-Sellers, Majed Khraishi, Luke Peterson, Anthony Turkiewicz, Jürgen Wollenhaupt, and Philip Mease

Link

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)., Désirée van der Heijde, Dafna D Gladman, Mitsumasa Kishimoto, Masato Okada, Suchitrita S Rathmann, Susan R Moriarty, Catherine L Shuler, Hilde Carlier, Olivier Benichou, and Philip J Mease

Link

Correction to: Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial., J A Walsh, A B Gottlieb, B Hoepken, T Nurminen, and P J Mease

Link

Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial., J A Walsh, A B Gottlieb, B Hoepken, T Nurminen, and P J Mease

Submissions from 2017

PDF

The feasibility of implementing the ICHOM Standard Set for Hip and Knee Osteoarthritis: a mixed-methods evaluation in public and private hospital settings., Ilana N Ackerman, Bernarda Cavka, Jacob Lippa, and Andrew Bucknill